The World Health Organization recommends this highly effective antiretroviral for all population groups, including young women.

Large European study finds that more than 1 in 10 people with HIV acquire HCV again.

On-demand, or 2-1-1, PrEP requires taking only four doses of Truvada during the days surrounding sex.

A recent study randomized those with a moderate long-term risk of heart attack to receive Crestor (rosuvastatin) or a placebo.

Researchers provided an initial Truvada prescription to eligible gay and bi men and trans women at their first appointment.

Nationwide, significant proportions of PrEP-using populations do not stay on Truvada for long.

The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.

Researchers analyzed data from 42 HIV centers in 11 Latin American nations.

The results of a poll in seven states “are alarming and should hasten our…efforts on viral suppression.” There’s also good news!

The attachment inhibitor plus an optimized antiretroviral background regimen suppressed HIV in the majority of study participants.